September 9, 2022 06:39 AM EDTUpdated September 12, 10:56 AM
Peer Review

Ho­mol­o­gy sails with same cap­tains in dif­fer­ent seats; Ex-Har­poon chief weath­ers the Storm at UK biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Af­ter a mul­ti-year run as co-work­ers at Shire Phar­ma­ceu­ti­cals, Arthur Tzian­a­bos and Al­bert Sey­mour got the band back to­geth­er in 2016 as two of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times